Journal issues > Issue Multiple Myeloma Special Edition, December 2018 > First-line treatment of non-transplant eligible multiple myeloma patients

First-line treatment of non-transplant eligible multiple myeloma patients

By: C. Doyen MD

SUMMARY

Multiple Myeloma (MM) is mainly a disease of the elderly. In 2018 bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone (Rd) are the established standard of care first-line regimens. Before starting therapy, an accurate evaluation of the frailty of patients is needed which allows physicians to individualize the approach for the individual patient.

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top